About Us

Fibronostics is a digital healthcare company shaping the future of noninvasive diagnostics for metabolic disease by applying neural network artificial intelligence to blood-based biomarkers.Our first generation products focused on patient identification screening and prognosis of chronic liver disease such as NAFLD/MAFLD and NASH.

The company is incorporated in Delaware with a fully-owned subsidiary in Singapore. We are currently commercially active in North America, Asia, Europe and LATAM.​

Interested about our science?

About Us

Fibronostics is a global diagnostics company, shaping the future of noninvasive diagnostics with artificial intelligence that provides algorithm-based solutions in a variety of diagnostic testing areas, focusing on patient identification screening, monitoring and prognosis of liver & kidney disease and other chronic conditions. (HBV, HCV, NAFLD, NASH, and ALD).
The company is incorporated in Delaware with a fully-owned subsidiary in Singapore. We are currently commercially active in North America, Asia, Europe and LATAM.​

Interested about our science?

Our Mission

To improve human health by bringing artificial intelligence-based solutions to the diagnosis of major metabolic diseases​.

Our team

Management

Sven Henrichwark

Chief Executive Officer

Dr Mona Munteanu

Chief Scientific Officer, PhD

Dr Ronald Quiambao

Chief Medical Officer MD, PhD

John Lee

Chief Technology Officer

Owen Parr

Vice President - Sales

Aida Jailani

Operations Director

Scientific Advisors

Dr. Imtiaz Alam

Clinical Associate Professor of Medicine Texas A&M University

Dr. Victor de Lédinghen

Head of the Hepatology & Liver Transplantation Unit, Bordeaux University Hospital

Dr. Scott Friedman

Professor of Medicine, Loma Linda University Loma Linda, CA

Dr. Meena Bansal

Professor of Medicine, Liver Diseases Mount Sinai, New York

Dr. Naim Alkhouri

VP of Academic Affairs, Chief of Transplant Hepatology,Arizona Liver Health, Phoenix, AZ